# Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

> **NCT05761444** · PHASE4 · COMPLETED · sponsor: **Organon and Co** · enrollment: 137 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Atozet 10/40 mg or 10/80 mg
- **DRUG:** Lipitor 40 mg or 80 mg

## Key facts

- **NCT ID:** NCT05761444
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-26
- **Primary completion:** 2024-09-04
- **Final completion:** 2024-10-15
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05761444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05761444, "Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05761444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*